These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 20009095)
1. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Hanley AJ; Zinman B; Sheridan P; Yusuf S; Gerstein HC; Diabetes Care; 2010 Mar; 33(3):608-13. PubMed ID: 20009095 [TBL] [Abstract][Full Text] [Related]
2. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. ; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075 [TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone. Osei K; Gaillard T; Schuster D Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222 [TBL] [Abstract][Full Text] [Related]
4. Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Rahman S; Ismail AA; Ismail SB; Naing NN; Abdul Rahman AR Eur J Clin Pharmacol; 2007 Aug; 63(8):733-41. PubMed ID: 17565489 [TBL] [Abstract][Full Text] [Related]
5. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR; J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351 [TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473 [TBL] [Abstract][Full Text] [Related]
7. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study. Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L J Intern Med; 2013 Apr; 273(4):410-21. PubMed ID: 23331339 [TBL] [Abstract][Full Text] [Related]
8. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test. RISE Consortium Diabetes Care; 2018 Aug; 41(8):1707-1716. PubMed ID: 29941498 [TBL] [Abstract][Full Text] [Related]
9. [Experiences of the DREAM trial]. Fövényi J Orv Hetil; 2006 Dec; 147(52):2523-6. PubMed ID: 17294577 [TBL] [Abstract][Full Text] [Related]
10. Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance. Bardini G; Dicembrini I; Rotella CM; Giannini S Acta Diabetol; 2013 Apr; 50(2):277-81. PubMed ID: 21997326 [TBL] [Abstract][Full Text] [Related]
11. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Durbin RJ Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752 [TBL] [Abstract][Full Text] [Related]
12. [The relation between fasting plasma glucose concentrations and insulin resistance]. Li L; Wang GX; Li P; Shang XJ; Liu C; Wang YJ; Yue GY Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):755-8. PubMed ID: 16255885 [TBL] [Abstract][Full Text] [Related]
13. Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Osei K; Gaillard T; Kaplow J; Bullock M; Schuster D Metabolism; 2004 Dec; 53(12):1552-7. PubMed ID: 15562399 [TBL] [Abstract][Full Text] [Related]
14. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Retnakaran R; Qi Y; Harris SB; Hanley AJ; Zinman B Diabetes Care; 2011 Jul; 34(7):1601-4. PubMed ID: 21709296 [TBL] [Abstract][Full Text] [Related]
15. Effect of ramipril on the incidence of diabetes. ; Bosch J; Yusuf S; Gerstein HC; Pogue J; Sheridan P; Dagenais G; Diaz R; Avezum A; Lanas F; Probstfield J; Fodor G; Holman RR N Engl J Med; 2006 Oct; 355(15):1551-62. PubMed ID: 16980380 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal decline of β-cell function: comparison of a direct method vs a fasting surrogate measure: the Insulin Resistance Atherosclerosis Study. Festa A; Haffner SM; Wagenknecht LE; Lorenzo C; Hanley AJ J Clin Endocrinol Metab; 2013 Oct; 98(10):4152-9. PubMed ID: 23884776 [TBL] [Abstract][Full Text] [Related]
17. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Qian L; Xu L; Wang X; Fu X; Gu Y; Lin F; Peng Y; Li G; Luo M Diabetes Metab Res Rev; 2009 Feb; 25(2):144-9. PubMed ID: 19116942 [TBL] [Abstract][Full Text] [Related]
18. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915 [TBL] [Abstract][Full Text] [Related]
19. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes. Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560 [TBL] [Abstract][Full Text] [Related]
20. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]